MX2018007756A - Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda. - Google Patents
Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.Info
- Publication number
- MX2018007756A MX2018007756A MX2018007756A MX2018007756A MX2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A
- Authority
- MX
- Mexico
- Prior art keywords
- lymphoblastic leukemia
- acute lymphoblastic
- antibodies
- treat acute
- bispecific
- Prior art date
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 title abstract 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 title abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title abstract 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
La presente invención proporciona métodos para tratar, reducir la gravedad o inhibir el crecimiento de la leucemia linfoblástica aguda. Los métodos de la presente invención comprenden administrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un anticuerpo biespecífico que se une específicamente a CD20 y CD3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562270749P | 2015-12-22 | 2015-12-22 | |
US201662306031P | 2016-03-09 | 2016-03-09 | |
PCT/US2016/068003 WO2017112762A1 (en) | 2015-12-22 | 2016-12-21 | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007756A true MX2018007756A (es) | 2018-08-09 |
Family
ID=57799832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007756A MX2018007756A (es) | 2015-12-22 | 2016-12-21 | Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170174781A1 (es) |
EP (1) | EP3394102A1 (es) |
JP (1) | JP2019503363A (es) |
KR (1) | KR20180087401A (es) |
CN (1) | CN108602889A (es) |
AU (1) | AU2016378573A1 (es) |
BR (1) | BR112018012929A2 (es) |
CA (1) | CA3009322A1 (es) |
EA (1) | EA201891495A1 (es) |
IL (1) | IL260000A (es) |
MA (1) | MA44145A (es) |
MX (1) | MX2018007756A (es) |
SG (1) | SG11201805048SA (es) |
WO (1) | WO2017112762A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
SG11201900201YA (en) | 2016-08-16 | 2019-02-27 | Regeneron Pharma | Methods for quantitating individual antibodies from a mixture |
SG11201902667UA (en) | 2016-10-25 | 2019-05-30 | Regeneron Pharma | Methods and systems for chromatography data analysis |
EP3807318A4 (en) * | 2018-06-14 | 2022-03-02 | BioAtla, Inc. | MULTISPECIFIC ANTIBODY CONSTRUCTS |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
US11157011B2 (en) * | 2018-07-30 | 2021-10-26 | Fedex Corporate Services, Inc. | Enhanced systems, apparatus, and methods for improved automated and autonomous operation of logistics ground support equipment |
JP2021535142A (ja) * | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Cd3/c20二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
WO2020092499A1 (en) | 2018-10-31 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
CN110563849B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
CN110498857B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
CN114206924A (zh) | 2019-12-06 | 2022-03-18 | 瑞泽恩制药公司 | 抗vegf蛋白组合物及其制备方法 |
TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗cd20x抗cd3雙特異性抗體之穩定調配物 |
WO2021245233A1 (en) * | 2020-06-04 | 2021-12-09 | Bioinvent International Ab | Improving antibody tolerabilty associated with intravenous administration |
CN112062855A (zh) | 2020-08-26 | 2020-12-11 | 康诺亚生物医药科技(成都)有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
CN114524878A (zh) | 2020-11-23 | 2022-05-24 | 康诺亚生物医药科技(成都)有限公司 | 一种双特异性抗体及其用途 |
AR127271A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1912675T1 (sl) * | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
NO2918604T3 (es) * | 2008-11-07 | 2018-05-19 | ||
TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-12-21 BR BR112018012929A patent/BR112018012929A2/pt not_active Application Discontinuation
- 2016-12-21 EA EA201891495A patent/EA201891495A1/ru unknown
- 2016-12-21 JP JP2018532790A patent/JP2019503363A/ja active Pending
- 2016-12-21 MX MX2018007756A patent/MX2018007756A/es unknown
- 2016-12-21 SG SG11201805048SA patent/SG11201805048SA/en unknown
- 2016-12-21 KR KR1020187018605A patent/KR20180087401A/ko unknown
- 2016-12-21 EP EP16826554.4A patent/EP3394102A1/en not_active Withdrawn
- 2016-12-21 CA CA3009322A patent/CA3009322A1/en not_active Abandoned
- 2016-12-21 CN CN201680076749.1A patent/CN108602889A/zh active Pending
- 2016-12-21 AU AU2016378573A patent/AU2016378573A1/en not_active Abandoned
- 2016-12-21 US US15/386,443 patent/US20170174781A1/en not_active Abandoned
- 2016-12-21 WO PCT/US2016/068003 patent/WO2017112762A1/en active Application Filing
- 2016-12-21 MA MA044145A patent/MA44145A/fr unknown
-
2018
- 2018-06-13 IL IL260000A patent/IL260000A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112018012929A2 (pt) | 2018-12-11 |
WO2017112762A1 (en) | 2017-06-29 |
JP2019503363A (ja) | 2019-02-07 |
MA44145A (fr) | 2018-10-31 |
US20170174781A1 (en) | 2017-06-22 |
SG11201805048SA (en) | 2018-07-30 |
CA3009322A1 (en) | 2017-06-29 |
KR20180087401A (ko) | 2018-08-01 |
IL260000A (en) | 2018-07-31 |
AU2016378573A1 (en) | 2018-07-19 |
EP3394102A1 (en) | 2018-10-31 |
CN108602889A (zh) | 2018-09-28 |
EA201891495A1 (ru) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018007756A (es) | Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda. | |
MX2018007613A (es) | Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer. | |
MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
MX2022004000A (es) | Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon. | |
PH12017500229A1 (en) | Combination therapies with anti cd40 antibodies | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
NZ728688A (en) | Anti-pd-1 antibodies | |
PH12020552115A1 (en) | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies | |
MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
WO2019094595A3 (en) | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
MX2020008569A (es) | Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer. | |
PH12019502313A1 (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
MX2014010987A (es) | Tratamiento de esclerosis multiple con anticuerpo anti-cd19. | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
MX2020006125A (es) | Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer. | |
MX2015011371A (es) | Anticuerpos monoclonales anti-+)--metanfetamina. | |
IL307821A (en) | Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody | |
MX2021002761A (es) | Metodos para tratar la pancreatitis. |